No insider purchase over the last 90 days. The latest, by Gupta Arun, was filed 14 Jun 2024.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate LXP Industrial Trust Buy (bullish), based on 5 analysts. Average price target: US$59.24.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 753 declarations
At LXP Industrial Trust, a US real estate company worth USD 3.6 billion, the gap between purchases and sales is small: 15 purchases worth EUR 811,299 (median EUR 47,087) and 17 sales worth EUR 4,162,348 (median EUR 201,352), so 47% of open-market trades are purchases. Most of the record lies elsewhere: of 597 filings, 505 are grants and 16 are option exercises.
The purchases come from directors. Arun Gupta bought EUR 124,154 on June 12, 2024, Richard Frary EUR 105,099 on May 10, 2022 and EUR 99,595 on June 13, 2022. From May 9 to May 23, 2022, 6 filers bought for EUR 332,903. Across the full history, 10 purchase filings are classed as clustered. The largest sales date from 2016 and 2017: Joseph Bonventre (EVP, GC and Secretary) EUR 865,472 on June 12, 2017, E. Robert Roskind (Chairman) EUR 600,886 on May 18, 2017 and EUR 470,437 on August 22, 2016.
T. Wilson Eglin, Chairman, CEO and President, has 54 filings. In all, 22 filers, 88 filings in 2019 and 19 in 2021. No purchase or sale in the last twelve months (37 filings). For 12 purchases, the stored 90-day results give a median of -3.8% with 25% positive (recorded past, not a forecast).
Insider filings
Over the last 90 days, 7 filings published on 7 October 2026: no open-market purchase or sale filed by an insider. 7 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers).
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 13 October 2026 (UTC)
| Fiscal year end | Revenue | Net income | Diluted EPS | Dividend per share | Filing |
|---|---|---|---|---|---|
| Dec 2025 | 350.2 m USD | 113.2 m USD | 1.82 USD | 2.70 USD | 10-K |
| Dec 2024 | 358.5 m USD | 44.5 m USD | 0.65 USD | 2.60 USD | 10-K |
| Dec 2023 | 340.5 m USD | 30.4 m USD | 0.41 USD | 2.50 USD | 10-K |
| Dec 2022 | 321.2 m USD | 113.8 m USD | 0.38 USD | 0.48 USD | 10-K |
| Dec 2021 | n.d. | 382.6 m USD | 1.34 USD | 0.44 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.